Market research
ATH.AU Alterity Therapeutics Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 56M
- P/E ratio
- Not available
- Analyst target
- 5.5167
- Dividend yield
- Not available
- Beta
- -0.01
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU0000043945
- Market cap
- 56M
- P/E ratio
- Not available
- Analyst target
- 5.5167
- Dividend yield
- Not available
- Beta
- -0.01
About
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Research context
Alterity Therapeutics Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ATH.AU discussion.
5 years, 6 months ago
Alterity Therapeutics Limited is currently in a long term uptrend where the price is trading 7.2% above its 200 day moving average.
From a valuation standpoint, the stock is 185.7% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 735.6.
Alterity Therapeutics Limited's total revenue sank by 53.6% to $7K since the same quarter in the previous year.
Its net income has dropped by 51.8% to $-9M since the same quarter in the previous year.
Finally, its free cash flow fell by 182.0% to $-4M since the same quarter in the previous year.
Based on the above factors, Alterity Therapeutics Limited gets an overall score of 1/5.